Is prevention the best treatment? CMV after lung transplantation

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 539-544

  Patel, N ^a   Snyder, L D ^b,c   Finlen Copeland, A ^b   Palmer, S M ^b,c  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

bronchiolitis obliterans syndrome; Cytomegalovirus; lung transplantation; prophylaxis

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTION; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LONG TERM CARE; LUNG TRANSPLANTATION; MORBIDITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VIRUS PNEUMONIA;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LUNG TRANSPLANTATION;

EID: 84857641899     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03837.x     Document Type: Review

References (27)

1. Zamora MR,. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4: 1219-1226. (Pubitemid 39013567)
2. Zuk DM, Humar A, Weinkauf JG, et al,. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90: 672-676.
3. Palmer SM, Limaye AP, Banks M, et al,. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation. Ann Intern Med 2010; 152: 761-769.
4. Valentine VG, Weill D, Gupta MR, et al,. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008; 27: 875-881.
5. Zamora MR, Nicolls MR, Hodges TN, et al,. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4: 1635-1642. (Pubitemid 39312297)
6. Singh N,. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704-708. (Pubitemid 40381344)
7. Singh N,. Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies. J Clin Virol 2006; 35: 474-477. (Pubitemid 43324850)
8. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
9. Christie JD, Edwards LB, Kucheryavay AY, et al,. The registry of the international society for heart and lung transplantation: Twenty-Seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010; 29: 1104-1118.
10. Kunsebeck HW, Kugler C, Fischer S, et al,. Quality of life and bronchiolitis obliterans syndrome. Prog Transplant 2007; 17: 136-141.
11. Snyder LD, Finlen-Copeland A, Turbyfill WJ, et al,. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 1391-1396.
12. Sharples LD, McNeil K, Stewart S, et al,. Risk Factors for bronchiolitis obliterans: A systemic review of recent publications. J Heart Lung Transplant 2002; 21: 271-281. (Pubitemid 34130545)
13. Tamm M, Aboyoun CL, Chhajed PN, et al,. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170: 1120-1123. (Pubitemid 39488626)
14. Weigt SS, Elashiff RM, Keane MP, et al,. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008; 8: 1512-1522. (Pubitemid 351989504)
15. Humar A,. Response to questions regarding the design and results of the IMPACT trial. Am J Transplant 2011; 11: 177-178.
16. Humar A, Michaels M,. American society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274. (Pubitemid 43382161)
17. Humar A, Kumar D, Preiksaitis J, et al,. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5: 1462-1468. (Pubitemid 40839439)
18. Palmer SM, Grinnan DC, Reams BD, et al,. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004; 18: 179-185. (Pubitemid 38404649)
19. Finlen-Copeland A, Davis A, Snyder LD, et al,. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011; 30: 990-996.
20. Jaksch P, Zweytick B, Kerschner H, et al,. Cytomegalovirus prevention in high-risk lung transplant recipients: Comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009; 28: 670-675.
21. Humar A, Limaye AP, Bumberg A, et al,. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-Year results of the IMPACT study. Transplantation 2010; 90: 1427-1430.
22. Weseslindtner L, Nachbagauer R, Kundi M, et al,. Human cytomegalovirus infection in lung transplant recipients triggers a CXCL-10 response. Am J Transplant 2011; 11: 542-552.
23. Mitsani D, Nguyen H, Girnita DM, et al,. A polymorphism linked to elevated levels of interferon-γ is associated with an increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center. J Heart Lung Transplant 2011; 30: 523-529.
24. Bunde T, Kirchner A, Hoffmeister B, et al,. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031-1036. (Pubitemid 40524670)
25. Westall GP, Mifsud NA, Kotsimbos T,. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8 +T-cell immunity. Am J Transplant 2008; 8: 1749-1754.
26. Snyder LD, Medinas R, Chan C, et al,. Polyfunctional cytomegalovirus- specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant 2011; 11: 553-560.
27. Pipeline MR, West EE, Osborne CM, et al,. Differential CMV-specific CD8+ effector T cell responses in the allograft predominate over the blood during human primary infection. J Immunol 2008; 181: 546-556.